At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 210 enrolled
Drug / intervention
Bexagliflozin +1 moredrug
Likely dose
Bexagliflozin 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Compare the Efficacy and Safety of Bexagliflozin to Placebo in Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control
In Brief
A Phase 3 clinical trial evaluating Bexagliflozin and Placebo for Type 2 Diabetes Mellitus. Completed, enrolled 210 participants across 23 sites in 2 countries.
Detailed Summary
The purpose of this study is to investigate the effect of bexagliflozin in lowering hemoglobin A1c (HbA1c) levels in patients with type 2 diabetes mellitus (T2DM).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesCanada, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartMar 2016
First PostedMar 2016
Primary CompletionApr 2017
TodayJul 2026
First PostedMar 22, 2016
Enrollment StartMar 1, 2016
Primary CompletionApr 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 10.3 years ago
Interventions
Bexagliflozindrug
tablets containing 20 mg bexagliflozin
Placebodrug
tablets matching the appearance of bexagliflozin tablets